Malignant histiocytosesC96.8

Last updated on: 21.10.2022

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Basically, the spectrum of malignant histiocytoses (MH) can be divided into:

  • primary malignant histiocytoses (manifest primarily in the skin)
  • and
  • secondary malignant histiocytoses (manifest primarily extracutaneously and secondarily affect the integument).

can be subdivided.

ClassificationThis section has been translated automatically.

HistologyThis section has been translated automatically.

Individual reports have documented identical immunoglobulin gene rearrangements suggesting a common clonal origin for both histiocytic/dendritic cell sarcoma sarcoma and B-cell neoplasm. Langerhans cell sarcoma is characterized by pleomorphic cytology, a high mitotic rate, and characteristic immunohistochemical staining for langerin, S100, and CD1a.

DiagnosisThis section has been translated automatically.

Phenotypic histological analysis (cells express markers of macrophages and/or Langerhans cells). Malignancies with B-cell differentiation are still to be excluded, as is "sarcoma of interdigitating dendritic cells".

Note(s)This section has been translated automatically.

With increasingly refined histological, immunological and molecular biological methods, it is now possible to assign many malignancies previously classified as malignant histiocytoses to T- or B-cell lymphomas. Especially anaplastic large cell CD30-positive T-cell lymphoma (historical name: atypical regressive histiocytosis) falls into this category. Severe cases of hemophagocytic lymphohistiocytosis (HLH) were also previously interpreted as malignant histiocytoses.

LiteratureThis section has been translated automatically.

  1. Furmanczyk PS et al (2012) Langerhans cell sarcoma in a patient with hairy cell leukemia: common clonal origin indicated by identical immunoglobulin gene rearrangements. J Cutan Pathol 39:644-650.
  2. Guo Y et al. (2022) Epstein-Barr virus-positive Langerhans cell sarcoma: Is There a Link? A Case Report. Front Oncol 11:769310
  3. Misery L (2003) Malignant Langerhans cell tumor: a case with a favorable outcome associated with the absence of blood dendritic cell proliferation. J Am Acad Dermatol 49: 527-529
  4. Tani M et al (1992) Malignant Langerhans cell tumour. Br J Dermatol 126:398-403.
  5. Mohanty P et al (2022) Unusual presentation of Langerhans cell sarcoma as bilateral submandibular gland swelling - A rare case report. Indian J Cancer 59:123-127.
  6. Nakamine H et al (2016) Langerhans cell histiocytosis and Langerhans cell sarcoma: Current Understanding and Differential Diagnosis. J Clin Exp Hematop 56:109-118.
  7. Subbiah V et al (2013) Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcoma. Ann Hematol 92:1149.

Last updated on: 21.10.2022